Products for Research Use Only

Nor-NOHA

CAT: 0804-HY-112885Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-112885Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Nor-NOHA is a selective and reversible arginase inhibitor. nor-NOHA induces apoptosis in ARG2-expressing cells under hypoxia. nor-NOHA has anti-leukemic activity. nor-NOHA can used in study of endothelial dysfunction, immunosuppression and metabolism[1][2].
CAS Number
189302-40-7
Product Name Alternative
Nω-Hydroxy-nor-L-arginine
UNSPSC
12352211
Hazard Statement
H302-H315-H319-H335
Target
Apoptosis; Arginase
Type
Reference compound
Related Pathways
Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Cancer; Metabolic Disease; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/nor-noha.html
Solubility
H2O : 250 mg/mL (ultrasonic)
Smiles
O=C(O)[C@@H](N)CCNC(NO)=N
Molecular Formula
C5H12N4O3
Molecular Weight
176.17
Precautions
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501
References & Citations
[1]Ng KP, et al. The arginase inhibitor Nω-hydroxy-nor-arginine (nor-NOHA) induces apoptosis in leukemic cells specifically under hypoxic conditions but CRISPR/Cas9 excludes arginase 2 (ARG2) as the functional target. PLoS One. 2018 Oct 11;13 (10) :e0205254.|[2]Jung C, et al. Arginase inhibition mediates cardioprotection during ischaemia-reperfusion. Cardiovasc Res. 2010 Jan 1;85 (1) :147-54.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 1
Citation 01
Clin Immunol. 2024 Sep 3:110355.|Cell. 2025 Dec 11;188 (25) :7291-7308.e23.|FASEB J. 2025 Sep 30;39 (18) :e71057.|Front Cell Dev Biol. 2021 Dec 23;9:741911.

Popular Products